WHAT IS GRX-917?

GRX-917

GRX-917 is a deuterated analog of etifoxine, an anxiety medication approved in France in 1979. GRX-917 has the same mechanism of action and pharmacological properties as the original non-deuterated form, because the biological properties are identical. Accordingly, etifoxine predicts the safety and efficacy of GRX-917.

Clinically, GRX-917’s speed of onset, efficacy and side effect profile will be identical to the original drug. However, the pharmacokinetic profile is significantly improved due to reduced metabolism from deuterium stabilization. This has lead to lower and less frequent dosing, from 200mg TID (etx) to 60mg QD (GRX). This improved dosing regiment should improve compliance. GRX-917 is shelf stable and ready for pivotal trials.